BioNTech SE (VIE:BNTX)
83.70
-2.40 (-2.79%)
At close: Sep 18, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
€339,439
Profits / Employee
€216,011
Market Cap
21.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Strabag SE | 80,923 |
| Erste Group Bank AG | 55,231 |
| Voestalpine AG | 48,641 |
| Raiffeisen Bank International AG | 41,704 |
| Vienna Insurance Group AG | 33,636 |
| Andritz AG | 30,557 |
| Telekom Austria AG | 16,616 |
| OMV Aktiengesellschaft | 15,936 |
BioNTech SE News
- 5 days ago - BioNTech says lung cancer drug candidate prolonged lives in trial - Reuters
- 5 days ago - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 21 days ago - BioNTech to terminate mid-stage trial of mRNA cancer vaccine - Reuters
- 22 days ago - US FDA approves updated COVID vaccines for 2026-27 season - Reuters
- 22 days ago - Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine - Business Wire
- 4 weeks ago - BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026 - GlobeNewsWire
- 6 weeks ago - BioNTech SE Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - BioNTech SE Earnings release: Q2 2026 - Filings